09.00 - 09.10 GMT

Robin Daly MBE

Welcome speach

09.10 - 09.55 GMT

Mark Sean Taylor

Mark Taylor of Patient Led Oncology, an organisation focused on understanding the scientific research of integrative oncology approaches, talks about how to navigate this increasingly complex world. Many patients are overwhelmed with information when diagnosed and don’t know which way to turn. After spending five years studying patients going through the experience of trying to navigate the confusion, he explains some common sense steps that leads to a greater chance of choosing an approach that works.

09.55 - 10.00 GMT

Comfort break

10.00 - 11.00 GMT

Prof Joachim Drevs

In many clinical studies, Aspirin is well proven for its preventive and adjuvant efficacy in all types of solid cancers. A similar salicylic acid, Diflunisal, has been used by us in a compassionate use programme since 2011. The particular mechanism of action of Diflunisal is highly effective, as demonstrated in patients with various cancer types, where a swift reduction in tumour burden has been observed. Additionally, this treatment has a secondary mode of action involving the immune system. The treatment protocol typically consists of five cycles, each lasting five days, and is generally well-tolerated. Despite its potent anticancer effects, the treatment's safety profile is considered favourable. Preliminary data from a pilot study suggest promising outcomes, with an approximate response rate of >60% for partial or complete remission and around 30% of patients achieving lasting remissions, regardless of tumour origin.

11.00 - 11.30 GMT

Time to visit our Sponsors pages

11.30 - 12.30 GMT

Dr Hűseyin Sahinbas

In the case of failure of guideline treatments for cancer, or when there is recurrence, there are limited treatment possibilities. If we are not able to cure our patient within conventional care, whether a primary cancer or in a metastatic or palliative situation, there is little realistic chance of helping in the long term. One possibility to increase success is to change the regimes of chemotherapy, and add new so called ‘intelligent agents’ such as antibodies or immune therapies. New surgical techniques or modern radiation methods can help us as well. But the successful treatment of cancer is highly complex and requires a coordinated interaction of all disciplines, utilising the right combination of treatment options from many areas. Personalised integrative medicine has a greater potential to help or cure patients by combining approaches such as hyperthermia, biologicals and oncolytic viruses.

12.30 - 14.00 GMT

Time to visit our Sponsors pages

14.00 - 15.00 GMT

Dr Oscar Orlandini and Daphy Cavero

Learn how being stuck in constant survival mode impacts cancer patient well-being, quality of life, and prognosis, and how combining different evidence-based integrative interventions, and practices can increase recovery, boost energy and emotional well-being, reduce stress and inflammation, and enhance patient resilience during treatment and beyond.

15.00 - 15.05 GMT

Confort Break

15.05 - 16.05 GMT

Dr Josep Carbonell

The first part of Dr Carbonell’s talk will address two techniques with a good evidence base that he finds are delivering good results: intratumoral cryoablation with immunotherapy drugs, and neoantigen vaccine with cytokine-induced killer cells and dendritic cells, supported by off label drugs, anti cancer IVs and hyperthermia.

In the second part of his lecture he will talk about an unknown Spanish drug/pharmacological compound based on urea, which is producing good responses, especially in breast cancer but also in other cancers. It has been applied in hundreds of cases with a significant increase in the quality of life of patients.

16.05 - 16.30 GMT

Time to visit our Sponsors pages

16.30 - 17.30 GMT

Dr Gary Onik

ImmunoOncology represents a revolution in the treatment of cancer. Harnessing a patient's own immune system to literally reject his/her cancer. The limitation of the systemic administration of these new miracle drugs is now becoming clear. Certain tumours, such as prostate, breast, and pancreatic cancer do not respond to systemic immunotherapy and the side effects associated with the systemic administration can be debilitating or even life threatening. In this presentation we will introduce Intratumoural immunotherapy as a new concept in cancer vaccine creation. Our experience will show that intratumoural administration can extend successful treatment to virtually all tumour types with minimal associated side effects.

17.30 - 17.50 GMT

Mark Sean Taylor

Mark pulls together his conclusions from the day and delivers some take-home messages to underpin the best choices in care.

17.50 - 18.00 GMT

Robin Daly MBE